Will Lewis, Insmed CEO, joins 'Fast Money' to talk Insmed's rare gene therapy development, demand, and quarterly results.
In honor of World Blindness Awareness Month, "GMA" is spotlighting a breakthrough gene therapy that's helping some blind ...
Phasmophobia is a year-round fear, but Halloween may trigger it further. Here's everything experts want you to know about the ...
UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today ...
Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...
Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...
An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...
Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback